Roche presents updated clinical trial data for hemlibra

SWITZERLAND – Roche has released results for its haemophilia A therapy candidate, Hemlibra which confirm that its has a favorable safety profile. In the analysis, no new safety signals were identified with long-term Hemlibra treatment in adults and adolescents with haemophilia A having inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. STASEY study data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, held from 17-21 July 2021. Final analysis of the STASEY study included data…

Read More

Roche set to participate at International Society on Thrombosis and Haemostasis 2021 congress

SWITZERLAND – Roche is set to participate in the International Society on Thrombosis and Haemostasis (ISTH) 2021 congress with new data on standard care for Haemophilia A. This virtual event will have Roche provide data that will include final analysis from the phase 3b STASEY study of Hemlibra (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group). Roche’s STASEY study is one of the largest open-label studies primarily assessing the safety and tolerability…

Read More